- AJOVY (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1
- Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed
- Full data presented as a late breaker at European Headache Cosgress (EHC) 4-7 December in Rotterdam, Netherlands
Teva Shares Phase 3 SPACE Trial Results Highlighting The Efficacy And Safety Of AJOVY (Fremanezumab) In Preventing Episodic Migraine In Children And Adolescents
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated